1,363
Participants
Start Date
April 19, 2018
Primary Completion Date
April 13, 2024
Study Completion Date
April 13, 2024
Dexamethasone
Given PO
Laboratory Biomarker Analysis
Correlative studies
Netupitant/Palonosetron Hydrochloride
Given PO
Olanzapine
Given PO
Placebo
Given PO
Prochlorperazine
Given PO
Quality-of-Life Assessment
Ancillary studies
University of Rochester NCORP Research Base, Rochester
Geisinger Cancer Institute NCORP, Danville
Southeast Clinical Oncology Research Program, Winston-Salem
Upstate Carolina NCORP, Spartanburg
Greenville NCORP, Greenville
Columbus NCORP, Columbus
Dayton Clinical Oncology Program, Dayton
Michigan Cancer Research Consortium, Ann Arbor
Cancer Research Consortium of West Michigan, Grand Rapids
Aurora NCORP, Milwaukee
Saint Vincent Hospital Cancer Center Green Bay, Green Bay
Gundersen Health System, La Crosse
Health Partners Inc, Minneapolis
Decatur Memorial Hospital, Decatur
Cancer Research for the Ozarks NCORP, Springfield
Gulf South MU-NCORP, New Orleans
Nevada Cancer Research Foundation NCORP, Las Vegas
Hawaii MU NCORP, Honolulu
National Cancer Institute (NCI)
NIH
University of Rochester NCORP Research Base
OTHER